We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]...
The Women In Trucking Association named Sue Spero, president of Carrier Services of Tennessee, the winner of the sixth annual Distinguished Woman in Logistics Award. ...
Capital Wealth Planning Chief Market Strategist Jeff Saut joins the On The Move panel to break down the market volatility amid the coronavirus pandemic. ...
Stocks rose Wednesday after a volatile session the prior day. Investors continued to monitor coronavirus developments, and early reports that the government was beginning to consider exit plans to restart businesses closed due to the outbreak....
(Bloomberg) -- Goldman Sachs Group Inc. is advising its wealthy clients to return to equities and particularly favors U.S. stocks on optimism for a strong economic recovery after the end of the virus lockdowns.“Our own advice to clients is that right now is a good time to get back into markets and take advantage of the decline in equity markets to position for the rebound,” Silvia Ardagna, managing director in the investment strategy group within Goldman Sachs Private Wealth Management, said in a phone interview.While Goldman strategists expect a sharp near-term decline in global economic activity, they also forecast a V-shaped rebound in the second half of the year. Ardagna said her team has been “positively impressed” by the response of policymakers and while these measures won’t prevent a recession in the first half, they’ll likely fuel a powerful recovery.Goldman’s investment strategy group recommended in mid-March that clients use the selloff...
Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens -- spike, envelop and membrane --selected for their vaccine candidate.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter."The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers. Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release. The company is now halfway through a four-milestone plan that it believes will lead to...